NL8204638A - Thioalkanoylcarnitinen, werkwijze ter bereiding ervan en mucolytische farmaceutische samenstellingen, die deze carnitinen bevatten. - Google Patents
Thioalkanoylcarnitinen, werkwijze ter bereiding ervan en mucolytische farmaceutische samenstellingen, die deze carnitinen bevatten. Download PDFInfo
- Publication number
- NL8204638A NL8204638A NL8204638A NL8204638A NL8204638A NL 8204638 A NL8204638 A NL 8204638A NL 8204638 A NL8204638 A NL 8204638A NL 8204638 A NL8204638 A NL 8204638A NL 8204638 A NL8204638 A NL 8204638A
- Authority
- NL
- Netherlands
- Prior art keywords
- compounds
- formula
- thioalkanoyl
- carnitines
- general formula
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 12
- 230000000510 mucolytic effect Effects 0.000 title claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 38
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- -1 halo anion Chemical class 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 206010011224 Cough Diseases 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 229960004203 carnitine Drugs 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims 1
- VWIOUOBDBMDNDG-UHFFFAOYSA-N C(C)(=S)CCC(=O)C(O)(C[N+](C)(C)C)CC([O-])=O Chemical compound C(C)(=S)CCC(=O)C(O)(C[N+](C)(C)C)CC([O-])=O VWIOUOBDBMDNDG-UHFFFAOYSA-N 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000001886 ciliary effect Effects 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 239000000829 suppository Substances 0.000 description 6
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 5
- 206010036790 Productive cough Diseases 0.000 description 5
- 229960004308 acetylcysteine Drugs 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 210000003802 sputum Anatomy 0.000 description 5
- 208000024794 sputum Diseases 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 4
- 229940001584 sodium metabisulfite Drugs 0.000 description 4
- 235000010262 sodium metabisulphite Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 238000010908 decantation Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- RJUIDDKTATZJFE-NSCUHMNNSA-N (e)-but-2-enoyl chloride Chemical compound C\C=C\C(Cl)=O RJUIDDKTATZJFE-NSCUHMNNSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- HMSQBVHZHCCRCG-UHFFFAOYSA-N 6-bromo-3-hydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]hexanoate Chemical compound BrCCC(=O)C(O)(C[N+](C)(C)C)CC([O-])=O HMSQBVHZHCCRCG-UHFFFAOYSA-N 0.000 description 1
- JGBXDYVDPIRVLO-UHFFFAOYSA-N C(C)(=S)C(CC(=O)C(O)(C[N+](C)(C)C)CC([O-])=O)C Chemical compound C(C)(=S)C(CC(=O)C(O)(C[N+](C)(C)C)CC([O-])=O)C JGBXDYVDPIRVLO-UHFFFAOYSA-N 0.000 description 1
- 102220474557 Connector enhancer of kinase suppressor of ras 1_C12S_mutation Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229960001009 acetylcarnitine Drugs 0.000 description 1
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- YKWNUSJLICDQEO-UHFFFAOYSA-N ethoxyethane;propan-2-ol Chemical compound CC(C)O.CCOCC YKWNUSJLICDQEO-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- JDKQTIKEGOOXTJ-UHFFFAOYSA-N pent-4-enoyl chloride Chemical compound ClC(=O)CCC=C JDKQTIKEGOOXTJ-UHFFFAOYSA-N 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/20—Esters of monothiocarboxylic acids
- C07C327/22—Esters of monothiocarboxylic acids having carbon atoms of esterified thiocarboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/20—Esters of monothiocarboxylic acids
- C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/009—Sachets, pouches characterised by the material or function of the envelope
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT49835/81A IT1172127B (it) | 1981-12-03 | 1981-12-03 | Tioacil - carnitine procedimento per la loro preparazione e composizioni farmaceutiche che le contengono ad azione mucclitica |
| IT4983581 | 1981-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8204638A true NL8204638A (nl) | 1983-07-01 |
Family
ID=11271675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8204638A NL8204638A (nl) | 1981-12-03 | 1982-11-30 | Thioalkanoylcarnitinen, werkwijze ter bereiding ervan en mucolytische farmaceutische samenstellingen, die deze carnitinen bevatten. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4518613A (sv) |
| JP (1) | JPS58113172A (sv) |
| KR (1) | KR890000617B1 (sv) |
| AT (1) | AT386408B (sv) |
| BE (1) | BE894959A (sv) |
| CA (1) | CA1188317A (sv) |
| CH (1) | CH651019A5 (sv) |
| DE (1) | DE3240112A1 (sv) |
| DK (1) | DK535482A (sv) |
| ES (1) | ES8401752A1 (sv) |
| FR (1) | FR2517672B1 (sv) |
| GB (1) | GB2110670B (sv) |
| IE (1) | IE53965B1 (sv) |
| IT (1) | IT1172127B (sv) |
| LU (1) | LU84496A1 (sv) |
| NL (1) | NL8204638A (sv) |
| SE (1) | SE453191B (sv) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3726945A1 (de) * | 1987-08-13 | 1989-02-23 | Dietl Hans | L-carnitinderivate der valproinsaeure und diese enthaltende arzneimittel |
| KR101552800B1 (ko) * | 2014-10-24 | 2015-09-11 | 허태준 | 유류탱크의 결로 및 유류유출 방지장치 |
| WO2018226854A2 (en) * | 2017-06-06 | 2018-12-13 | Wayne State University | Antifouling polymer coatings and reverse coating method |
| KR102499363B1 (ko) * | 2022-01-27 | 2023-02-13 | 주식회사 성문 | 컨테이너 외부 단열 방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6022045B2 (ja) * | 1977-11-17 | 1985-05-30 | 日本冶金工業株式会社 | 冷却材の添加方法 |
| JPS5579821A (en) * | 1978-12-11 | 1980-06-16 | Japan Steel Works Ltd:The | Manufacture of low-carbon high-chromium alloy steel by heat-insulated furnace for molten steel |
| IT1116037B (it) * | 1979-04-23 | 1986-02-10 | Sigma Tau Ind Farmaceuti | Esteri e ammidi di acil carnitine loro procedimenti di preparazione e loro uso terapeutico |
| JPS56130419A (en) * | 1980-03-15 | 1981-10-13 | Nippon Steel Corp | Production of chromium-containing steel |
| US4327111A (en) * | 1980-07-14 | 1982-04-27 | E. R. Squibb & Sons, Inc. | N-Substituted mercaptoacyl pripionamides |
-
1981
- 1981-12-03 IT IT49835/81A patent/IT1172127B/it active
-
1982
- 1982-10-08 CH CH5917/82A patent/CH651019A5/it not_active IP Right Cessation
- 1982-10-22 IE IE2553/82A patent/IE53965B1/en not_active IP Right Cessation
- 1982-10-22 US US06/436,190 patent/US4518613A/en not_active Expired - Fee Related
- 1982-10-28 SE SE8206129A patent/SE453191B/sv not_active IP Right Cessation
- 1982-10-29 DE DE19823240112 patent/DE3240112A1/de active Granted
- 1982-11-03 GB GB08231450A patent/GB2110670B/en not_active Expired
- 1982-11-09 CA CA000415170A patent/CA1188317A/en not_active Expired
- 1982-11-09 BE BE0/209435A patent/BE894959A/fr not_active IP Right Cessation
- 1982-11-19 KR KR8205236A patent/KR890000617B1/ko active
- 1982-11-24 FR FR8219673A patent/FR2517672B1/fr not_active Expired
- 1982-11-30 NL NL8204638A patent/NL8204638A/nl not_active Application Discontinuation
- 1982-12-01 JP JP57212073A patent/JPS58113172A/ja active Granted
- 1982-12-01 LU LU84496A patent/LU84496A1/xx unknown
- 1982-12-02 AT AT0438182A patent/AT386408B/de not_active IP Right Cessation
- 1982-12-02 ES ES517888A patent/ES8401752A1/es not_active Expired
- 1982-12-02 DK DK535482A patent/DK535482A/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DK535482A (da) | 1983-06-04 |
| FR2517672B1 (fr) | 1987-06-19 |
| KR840002351A (ko) | 1984-06-25 |
| DE3240112A1 (de) | 1983-06-09 |
| AT386408B (de) | 1988-08-25 |
| IE822553L (en) | 1983-06-03 |
| CH651019A5 (it) | 1985-08-30 |
| GB2110670A (en) | 1983-06-22 |
| IE53965B1 (en) | 1989-04-26 |
| GB2110670B (en) | 1985-06-12 |
| JPS58113172A (ja) | 1983-07-05 |
| FR2517672A1 (fr) | 1983-06-10 |
| ES517888A0 (es) | 1984-01-01 |
| JPH0332545B2 (sv) | 1991-05-13 |
| DE3240112C2 (sv) | 1992-06-25 |
| KR890000617B1 (ko) | 1989-03-22 |
| ES8401752A1 (es) | 1984-01-01 |
| SE453191B (sv) | 1988-01-18 |
| SE8206129L (sv) | 1983-06-04 |
| SE8206129D0 (sv) | 1982-10-28 |
| IT1172127B (it) | 1987-06-18 |
| ATA438182A (de) | 1988-01-15 |
| LU84496A1 (fr) | 1983-06-13 |
| IT8149835A0 (it) | 1981-12-03 |
| BE894959A (fr) | 1983-03-01 |
| CA1188317A (en) | 1985-06-04 |
| US4518613A (en) | 1985-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0025692B1 (en) | Quinone derivatives, their production and use | |
| EP2186792B1 (en) | 2-(a-hydroxypentyl) benzoate and its preparation and use | |
| US4330677A (en) | Polyether compounds, their production and their medicinal use | |
| EP2404894B1 (en) | Mevalonic Acid Derivatives | |
| US20160250339A1 (en) | Pegylated Artesunate Derivative, Pharmaceutical Composition and Use Thereof | |
| JPS59163400A (ja) | ウルソデソキシコ−ル酸硫酸エステルのナトリウム塩 | |
| SE450251B (sv) | Xantatforeningar for terapeutisk anvendning, nya xantatforeningar samt terapeutiska kompositioner innehallande dessa foreningar | |
| CN1127480C (zh) | 秋水仙素衍生物及其治疗用途 | |
| NL8204638A (nl) | Thioalkanoylcarnitinen, werkwijze ter bereiding ervan en mucolytische farmaceutische samenstellingen, die deze carnitinen bevatten. | |
| CA1167864A (en) | Esters of mercapto acyl-carnitines, process for their preparation and pharmaceutical compositions containing same | |
| US20210009620A1 (en) | Pure heptasulfated disaccharides having improved oral bioavailability | |
| CN111518157B (zh) | 一种雷公藤甲素衍生物及其制备方法和应用 | |
| KR860001903B1 (ko) | 메르캅토 아실-카르니틴의 제조방법 | |
| US3732295A (en) | Trimethoxybenzoyl-aminoalkanoic acids | |
| JP2878844B2 (ja) | Ｎ▲ｇ▼−モノメチル−ｌ−アルギニン塩酸塩誘導体および敗血性ショックの治療におけるこれらの使用 | |
| Ainsworth et al. | Cholesterol-solubilizing agents related to the gallstone problem | |
| CA1174978A (en) | Xanthates | |
| US4472424A (en) | Esters of 2-thenoylmercaptopropionylglycine with substituted hydroxybenzenes, process for their preparation and pharmaceutical compositions containing same | |
| EP0218356B1 (en) | Phenylalanine derivatives and uses thereof | |
| US4218447A (en) | Acyl derivatives of hellebrigenin | |
| AU2020375675B2 (en) | Expectorant compound and preparation method and use thereof | |
| CN117924325A (zh) | 一种抗流感病毒衍生物及其用途 | |
| EP0394684A1 (en) | Immunopotentiator and spergualin-related compound therefor | |
| JPH0377898A (ja) | シアロシルコレステロールからなる筋ジストロフィー症治療剤 | |
| KR19990072051A (ko) | 티아민디술피드류및이를유효성분으로하는의약 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A85 | Still pending on 85-01-01 | ||
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| BV | The patent application has lapsed |